News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
Wilmington, Del., December 12, 2023 -- Hyfe, Inc., the global leader in AI-powered cough detection, tracking, and classification, today announces breakthrough results from a performance evaluation study comparing human cough annotators to emerging automated technologies using AI and machine learning. The BMJ Open Respiratory Research study demonstrates Hyfe’s cough detection AI technology is nearly as accurate as the human ear in analyzing the amount and duration of cough in a real-world environment.
The study analyzed 40 hours of audio randomly collected from participants wearing audio recording smartwatches throughout an average day. The audio samples were manually reviewed and annotated twice by one expert human annotator and some samples of the 40 hours were annotated a third time by six of Hyfe’s expert annotators. Key insights from the study include:
Notably, the study is also the first to observe sex differences in cough, observing for the first time that the duration of cough sounds and epoch size differed between male and female participants. The study found that women tend to have shorter cough sounds but more coughs in each episode compared to men. These observed differences in cough characteristics could have important implications for the development of cough monitoring tools. They will be key in better understanding how diseases spread, diagnosing illnesses, and how people seek medical help.
We’re thrilled that the results of this study confirm the accuracy of our robust automated cough monitoring technology. These findings pave the way for more accurate, reliable, and clinically relevant methods for cough tracking. They provide valuable insights that could significantly impact the much-needed development for monitoring coughs in healthcare and clinical trial settings. These are breakthrough discoveries in the chronic cough space, and we look forward to taking an even deeper look into cough in future studies like this.
Joe Brew
CEO of Hyfe AI
Hyfe is the leader in longitudinal cough monitoring with over 700 million sounds in its cough database. It can track and detect cough with 90%+ accuracy on any mic-enabled device with no need for patient intervention while preserving patient privacy.
For more information, visit hyfe.com.
About Hyfe
Hyfe, Inc. is the global leader in AI-powered cough detection and classification that provides insight into cough patterns and correlations and is being widely used to help patients gain a better understanding of their cough and have more informed conversations with their providers. With more than 700 million samples, Hyfe maintains the largest cough dataset in the world enabling the building of powerful models to track, manage and diagnose respiratory illnesses. Hyfe provides platforms and data for pharmaceutical companies, medical researchers, government agencies, health care providers and patients and has partnerships with leading academic institutions including Johns Hopkins University and the University of California at San Francisco. The company was founded in 2020 and is headquartered in Wilmington, Delaware. More information is available at hyfe.com on social media @hyfeapp and LinkedIn at /hyfe.
###
Contact:
press@hyfe.ai
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.